BMS To Pay $2.1M To Settle FTC's Plavix Claims

Law360, New York (March 27, 2009, 12:00 AM EDT) -- Bristol-Myers Squibb Co. has agreed to fork over $2.1 million to settle allegations by the U.S. Federal Trade Commission that the drugmaker issued misleading statements about a proposed Plavix patent deal with Apotex Corp. in 2006, violating court orders stemming from two earlier antitrust cases.

The deal will lay to rest a lawsuit filed Thursday by the FTC in the U.S. District Court for the District of Columbia accusing Bristol-Myers of concealing material information about its agreement with the Canadian pharmaceutical company to keep a copycat...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.